GLP-1/glucagon coagonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic diet
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
GLP-1/glucagon coagonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic diet. / Clemmensen, Christoffer; Chabenne, Joseph; Finan, Brian; Sullivan, Lorraine; Fischer, Katrin; Küchler, Daniela; Sehrer, Laura; Ograjsek, Teja; Hofmann, Susanna M; Schriever, Sonja C; Pfluger, Paul T; Pinkstaff, Jason; Tschöp, Matthias H; Dimarchi, Richard; Müller, Timo D.
In: Diabetes, Vol. 63, No. 4, 04.2014, p. 1422-7.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - GLP-1/glucagon coagonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic diet
AU - Clemmensen, Christoffer
AU - Chabenne, Joseph
AU - Finan, Brian
AU - Sullivan, Lorraine
AU - Fischer, Katrin
AU - Küchler, Daniela
AU - Sehrer, Laura
AU - Ograjsek, Teja
AU - Hofmann, Susanna M
AU - Schriever, Sonja C
AU - Pfluger, Paul T
AU - Pinkstaff, Jason
AU - Tschöp, Matthias H
AU - Dimarchi, Richard
AU - Müller, Timo D
PY - 2014/4
Y1 - 2014/4
N2 - We recently reported restoration of leptin responsiveness in diet-induced obese (DIO) mice using a pharmacologically optimized, polyethylene-glycolated (PEG)-leptin analog in combination with exendin-4 or FGF21. However, the return of leptin action required discontinuation of high-fat diet (HFD) exposure. Here we assess whether a single peptide possessing balanced coagonism at the glucagon-like peptide 1 (GLP-1) and glucagon receptors can restore leptin responsiveness in DIO mice maintained on a HFD. DIO mice were treated with PEG-GLP-1/glucagon (30 nmol/kg every fourth day) to induce an ∼15% body weight loss, upon which they were randomized to continue PEG-GLP-1/glucagon therapy or reassigned to receive supplemental daily PEG-leptin (185 nmol/kg/day). The addition of PEG-leptin to PEG-GLP-1/glucagon resulted in an ∼18% greater weight loss as compared with PEG-GLP-1/glucagon alone and was accompanied by further decreases in food intake and improved glucose and lipid metabolism. The beneficial effect of PEG-leptin supplementation occurred after an initial body weight loss similar to what we previously reported following reduced dietary fat along with PEG-leptin and exendin-4 or FGF21 cotreatment. In summary, we report that GLP-1/glucagon coagonism restores leptin responsiveness in mice maintained on a HFD, thus emphasizing the translational value of this polypharmacotherapy for the treatment of obesity and diabetes.
AB - We recently reported restoration of leptin responsiveness in diet-induced obese (DIO) mice using a pharmacologically optimized, polyethylene-glycolated (PEG)-leptin analog in combination with exendin-4 or FGF21. However, the return of leptin action required discontinuation of high-fat diet (HFD) exposure. Here we assess whether a single peptide possessing balanced coagonism at the glucagon-like peptide 1 (GLP-1) and glucagon receptors can restore leptin responsiveness in DIO mice maintained on a HFD. DIO mice were treated with PEG-GLP-1/glucagon (30 nmol/kg every fourth day) to induce an ∼15% body weight loss, upon which they were randomized to continue PEG-GLP-1/glucagon therapy or reassigned to receive supplemental daily PEG-leptin (185 nmol/kg/day). The addition of PEG-leptin to PEG-GLP-1/glucagon resulted in an ∼18% greater weight loss as compared with PEG-GLP-1/glucagon alone and was accompanied by further decreases in food intake and improved glucose and lipid metabolism. The beneficial effect of PEG-leptin supplementation occurred after an initial body weight loss similar to what we previously reported following reduced dietary fat along with PEG-leptin and exendin-4 or FGF21 cotreatment. In summary, we report that GLP-1/glucagon coagonism restores leptin responsiveness in mice maintained on a HFD, thus emphasizing the translational value of this polypharmacotherapy for the treatment of obesity and diabetes.
KW - Animals
KW - Diet, High-Fat
KW - Eating
KW - Feeding Behavior
KW - Glucagon
KW - Glucagon-Like Peptide 1
KW - Leptin
KW - Male
KW - Mice
KW - Mice, Inbred C57BL
KW - Mice, Obese
KW - Obesity
KW - Polyethylene Glycols
KW - Receptors, Glucagon
KW - Weight Loss
KW - Journal Article
KW - Research Support, Non-U.S. Gov't
U2 - 10.2337/db13-1609
DO - 10.2337/db13-1609
M3 - Journal article
C2 - 24379349
VL - 63
SP - 1422
EP - 1427
JO - Diabetes
JF - Diabetes
SN - 0012-1797
IS - 4
ER -
ID: 186640652